Furthermore, to remove the impact of systemic and airway inflammation on muscle atrophy, we excluded not only patients with persistent oral glucocorticoid use in our research study but also patients with serum CRP and FeNO levels in COPD and controls. The gene discussed is CRP; the disease is chronic obstructive pulmonary disease.